Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
07/05/2026 13:23
May 7 (Reuters) - AIM ImmunoTech Inc AIM.A: AIM IMMUNOTECH ANNOUNCES 50% OBJECTIVE RESPONSE RATE (ORR) IN UPMC RECURRENT OVARIAN CANCER PHASE 2 CLINICAL TRIAL, SUGGESTING BREAKTHROUGH COMBINATION POTENTIAL AIM IMMUNOTECH INC - SECONDARY ENDPOINT DATA COLLECTION EXPECTED TO COMPLETE IN JANUARY 2027 Source text: ID:nGNX9R3Fkz Further company coverage: AIM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential